I wish it was my biggest disaster this year! :) I've for some reason had several. Nothing earth shattering, but not a good year for me, especially compared to the last two.
Yes, I like the orphan drug status. I'm no expert, but I also think that it's not really a drug that generic companies would be really trying to jump into. There's side-effect potential and not a lot of patients.
But, I'm hoping SVNT is about to get a J code for KRYSTEXXA for the new year, which hopefully will get a ramp up going. The thing is, at $50k/year, there's not a lot of patients needed to justify this market cap. I think the word is out there after the last year of salesmen being out on the road. And my hunch is that the drug is still working pretty well for a limited number of patients. So, my view is that it's just a high-price issue, and once we get that figured out with the insurance, I think we're in business to at least get a few thousand clients, which will justify the market cap. I think DNDN is running into the same issues.
And there's Europe as you mentioned. I think there's decent hope for this one, and they should have the cash to play out the ramp-up. We'll see though...
-Grant |
